Cite
HARVARD Citation
Gibb, A. et al. (n.d.). RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY). Hematological oncology. pp. 80-81. [Online].